跳转至内容
Merck
CN
  • A lower degree of PBMC L1 methylation in women with lower folate status may explain the MTHFR C677T polymorphism associated higher risk of CIN in the US post folic acid fortification era.

A lower degree of PBMC L1 methylation in women with lower folate status may explain the MTHFR C677T polymorphism associated higher risk of CIN in the US post folic acid fortification era.

PloS one (2014-10-11)
Suguna Badiga, Gary L Johanning, Maurizio Macaluso, Andres Azuero, Michelle M Chambers, Nuzhat R Siddiqui, Chandrika J Piyathilake
摘要

Studies in populations unexposed to folic acid (FA) fortification have demonstrated that MTHFR C677T polymorphism is associated with increased risk of higher grades of cervical intraepithelial neoplasia (CIN 2+). However, it is unknown whether exposure to higher folate as a result of the FA fortification program has altered the association between MTHFR C677T and risk of CIN, or the mechanisms involved with such alterations. The current study investigated the following in a FA fortified population: 1) The association between MTHFR C677T polymorphism and risk of CIN 2+; 2) The modifying effects of plasma folate concentrations on this association; and 3) The modifying effects of plasma folate on the association between the polymorphism and degree of methylation of long interspersed nucleotide elements (L1s), in peripheral blood mononuclear cell (PBMC) DNA, a documented biomarker of CIN risk. The study included 457 US women diagnosed with either CIN 2+ (cases) or ≤ CIN 1 (non-cases). Unconditional logistic regression models were used to test the associations after adjusting for relevant risk factors for CIN. The 677CT/TT MTHFR genotypes were not associated with the risk of CIN 2+. Women with CT/TT genotype with lower folate, however, were more likely to be diagnosed with CIN 2+ compared to women with CT/TT genotype with higher folate (OR = 2.41, P = 0.030). Women with CT/TT genotype with lower folate were less likely to have a higher degree of PBMC L1 methylation compared to women with CT/TT genotype with higher folate (OR = 0.28, P = 0.017). This study provides the first evidence that the MTHFR 677CT/TT genotype-associated lower degree of PBMC L1 methylation increases the risk of CIN 2+ in women in the US post-FA fortification era. Thus, even in the post-FA fortification era, not all women have adequate folate status to overcome MTHFR 677CT/TT genotype-associated lower degree of L1 methylation.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
L -抗坏血酸, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
L -抗坏血酸, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
L -抗坏血酸, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
L -抗坏血酸, 99%
Sigma-Aldrich
L -抗坏血酸, reagent grade, crystalline
Supelco
维生素C, Pharmaceutical Secondary Standard; Certified Reference Material
USP
抗坏血酸, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
L -抗坏血酸, ACS reagent, ≥99%
Supelco
L -抗坏血酸, analytical standard
Sigma-Aldrich
L -抗坏血酸, meets USP testing specifications
Sigma-Aldrich
L -抗坏血酸, reagent grade
Sigma-Aldrich
L -抗坏血酸, puriss. p.a., ACS reagent, reag. ISO, Ph. Eur., 99.7-100.5% (oxidimetric)
Sigma-Aldrich
L -抗坏血酸, FCC, FG
Sigma-Aldrich
L -抗坏血酸, BioUltra, ≥99.5% (RT)
维生素C, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
L -抗坏血酸, puriss. p.a., ≥99.0% (RT)
Supelco
L -抗坏血酸, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L -抗坏血酸, tested according to Ph. Eur.
Sigma-Aldrich
L -抗坏血酸, Vetec, reagent grade, 99%